title: Somatostatin receptor scintigraphy screening in advanced hepatocarcinoma: A multi-center French study.
abstract: BACKGROUND
  Somatostatin receptor scintigraphy (SRS) has been reported for receptor (SSTR) screening in advanced hepatocarcinoma (aHC) prior to somatostatin analogue treatment.
  
  
  OBJECTIVE
  To evaluate SSTR screening with SRS in aHC patients.
  
  
  RESULTS
  Seventy aHC patients (63 men) aged 65 +/- 11 y were included, with alcohol, viral or other causes cirrhosis in 35 (50%), 23 (33%), 12 (17%) cases respectively. CLIP score was 2.7 +/- 1.7, with more than three nodules in 37 (53%) cases. Largest nodule measured 7.6 +/- 4.5 cm. Median alpha-fetoprotein was 574 UI/mL. SRS was positive in 25/70 (35.7%) livers and 7/17 (41.2%) metastatic sites. Positive SRS patients differed from others for tumor size (9.2 +/- 4 vs. 6.7 +/- 4.6 cm, p = 0.03), prothrombin time (PT) (75.2 +/- 15.2 vs. 61.9 +/- 19%, p = 0.005), albumin (34.1 +/- 5.9 vs. 30.5 +/- 7.2 g/L, p = 0.04) and Child-Pugh (6.7 +/- 1.8 vs. 7.7 +/- 2.3, p = 0.04). After multivariate analysis, only PT was associated with positive SRS (p = 0.028). Immunohistochemistry was positive for SSTR2s in 6/7 tumors (SRS uptake in 5/6 cases).
  
  
  METHODS
  SRS was performed prior treatment, with images at 4, 24 and 48 h. For seven tumors, SSTR2 subtype was detected immunohistochemically.
  
  
  CONCLUSIONS
  In advanced hepatocarcinoma, we report SRS uptake in 35.7% of livers and 41.2% of metastatic sites. SRS value in screening patients for somatostatin analogue treatment remains to be assessed.
authors.affiliation: Service d'Hépato-Gastroentérologie CHU Amiens, Amiens, France. nguyen-khac.eric@chu-amiens.fr
authors.forename: Eric
authors.initials: E
authors.lastname: Nguyen-Khac
authors.forename: Isabelle
authors.initials: I
authors.lastname: Ollivier
authors.forename: Thomas
authors.initials: T
authors.lastname: Aparicio
authors.forename: Véronique
authors.initials: V
authors.lastname: Moullart
authors.forename: Alexis
authors.initials: A
authors.lastname: Hugentobler
authors.forename: Rachida
authors.initials: R
authors.lastname: Lebtahi
authors.forename: Céline
authors.initials: C
authors.lastname: Lobry
authors.forename: Christiane
authors.initials: C
authors.lastname: Susini
authors.forename: Christian
authors.initials: C
authors.lastname: Duhamel
authors.forename: Séverine
authors.initials: S
authors.lastname: Hommel
authors.forename: Jean François
authors.initials: JF
authors.lastname: Cadranel
authors.forename: Jean-paul
authors.initials: JP
authors.lastname: Joly
authors.forename: Jean Claude
authors.initials: JC
authors.lastname: Barbare
authors.forename: Blaise
authors.initials: B
authors.lastname: Tramier
authors.forename: Jean Louis
authors.initials: JL
authors.lastname: Dupas
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D005602:France; D006801:Humans; D007150:Immunohistochemistry; D007205:Indium Radioisotopes / Q000493:pharmacokinetics; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011877:Radionuclide Imaging / Q000379:methods; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D017481:Receptors, Somatostatin / Q000032:analysis* / Q000378:metabolism; D013004:Somatostatin / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D016896:Treatment Outcome
chemical_list: D007205:Indium Radioisotopes; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; D013004:Somatostatin; C081788:pentetreotide